Exclusive Summary

• Originator patents have completely expired globally, allowing overseas distributors to register and commercialize the product rapidly without any intellectual property infringement risks.
• Confronting a staggering population of over 537 million explicit adult diabetics globally, this combination therapy captures a massive, chronic, and sustained market demand.
• The fixed-dose combination remarkably improves long-term medication adherence for patients, providing essential titration strengths that fulfill varied clinical requirements.
• Leveraging China's deeply integrated API upstream supply chain, the product boasts an overwhelming cost advantage, making it exceptionally competitive for both public healthcare tenders and retail distribution.
• Backed by internationally recognized GMP standards and comprehensively prepared CTD dossiers, partners are empowered to expedite regulatory approvals and proactively secure target markets.